857 related articles for article (PubMed ID: 25327734)
21. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
Yagi H; Yotsumoto F; Miyamoto S
Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
[TBL] [Abstract][Full Text] [Related]
22. [Impact of hypoxia on taxol-induced apoptosis in human ovarian cancer cell line A2780 and its mechanism].
Huang L; Ao QL; Li F; Xing H; Lu YP; Ma D
Ai Zheng; 2005 Apr; 24(4):408-13. PubMed ID: 15820061
[TBL] [Abstract][Full Text] [Related]
23. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract][Full Text] [Related]
24. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.
Sanui A; Yotsumoto F; Tsujioka H; Fukami T; Horiuchi S; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3143-9. PubMed ID: 20871033
[TBL] [Abstract][Full Text] [Related]
25. [Study on the Relationship Between
Yue C; Li RH; Chen C; Liu H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 May; 49(3):337-341. PubMed ID: 30014630
[TBL] [Abstract][Full Text] [Related]
26. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.
Mo QQ; Chen PB; Jin X; Chen Q; Tang L; Wang BB; Li KZ; Wu P; Fang Y; Wang SX; Zhou JF; Ma D; Chen G
Acta Pharmacol Sin; 2013 Apr; 34(4):541-8. PubMed ID: 23474708
[TBL] [Abstract][Full Text] [Related]
28. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
[TBL] [Abstract][Full Text] [Related]
29. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells.
Lu M; Xiao L; Li Z
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):725-8. PubMed ID: 18231754
[TBL] [Abstract][Full Text] [Related]
30. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
31. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
[TBL] [Abstract][Full Text] [Related]
32. Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.
Miyata K; Yotsumoto F; Nam SO; Odawara T; Manabe S; Ishikawa T; Itamochi H; Kigawa J; Takada S; Asahara H; Kuroki M; Miyamoto S
Cancer Med; 2014 Oct; 3(5):1159-69. PubMed ID: 25060396
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
Huang GS; Brouwer-Visser J; Ramirez MJ; Kim CH; Hebert TM; Lin J; Arias-Pulido H; Qualls CR; Prossnitz ER; Goldberg GL; Smith HO; Horwitz SB
Clin Cancer Res; 2010 Jun; 16(11):2999-3010. PubMed ID: 20404007
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant.
Rivetti S; Lauriola M; Voltattorni M; Bianchini M; Martini D; Ceccarelli C; Palmieri A; Mattei G; Franchi M; Ugolini G; Rosati G; Montroni I; Taffurelli M; Solmi R
Int J Immunopathol Pharmacol; 2011; 24(3):639-49. PubMed ID: 21978696
[TBL] [Abstract][Full Text] [Related]
36. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
[TBL] [Abstract][Full Text] [Related]
37. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Wang C; Guo LB; Ma JY; Li YM; Liu HM
Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547
[TBL] [Abstract][Full Text] [Related]
38. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
39. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197.
Martarelli D; Pompei P; Mazzoni G
Chemotherapy; 2009; 55(6):425-32. PubMed ID: 19996587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
